See more : Shree Rama Multi-Tech Limited (SHREERAMA.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Kilitch Drugs (India) Limited (KILITCH.BO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kilitch Drugs (India) Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- 12 ReTech Corporation (RETC) Income Statement Analysis – Financial Results
- Eneti Inc. (NETI) Income Statement Analysis – Financial Results
- C.Q. Pharmaceutical Holding Co., Ltd. (000950.SZ) Income Statement Analysis – Financial Results
- Taisun Int’l (Holding) Corporation (8480.TW) Income Statement Analysis – Financial Results
- China Ocean Group Development Limited (8047.HK) Income Statement Analysis – Financial Results
Kilitch Drugs (India) Limited (KILITCH.BO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.kilitch.com
About Kilitch Drugs (India) Limited
Kilitch Drugs (India) Limited engages in the development and operation of pharmaceutical business in India. The company offers parenteral and nasal products, including gastroenterology, anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, non-steroidal anti-inflammatory, oncology, ophthalmic, and other drugs, as well as vaccines and veterinary products in the form of liquid ampoules, vials, and dry powder injectables. Its parenteral and nasal products also include iron supplements for the treatment of anemia; and metered nasal drops, as well as Klavmox and Onecef products. The company also provides a range of oral formulations, including tablets, capsules, dry syrup, gripe water, and oral powder and liquid in the antibiotic, anti-diabetics, cardiovascular, and other areas. In addition, it offers effervescent tablets and powders, such as ROIPAR, DUREGRA, ROIVIT, and PH-7; and various nutritional products, such as CELTINE. Further, the company provides C-Seal, a topical skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Additionally, it offers cosmetics and herbal products consisting of a range of oils, lotions, liquids, creams, and paste in skin, personal, and hair care categories, as well as herbal products used in sore throat and prostate problems; and as a supplement for diabetes, obesity, libido, and other conditions. The company also exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 1.54B | 1.39B | 1.13B | 681.28M | 491.45M | 814.28M | 499.12M | 271.61M | 209.85M | 190.27M | 148.98M | 331.81M | 1.08B | 1.46B | 1.43B | 1.29B | 1.17B | 323.84M |
Cost of Revenue | 923.25M | 771.35M | 682.53M | 381.22M | 297.69M | 488.34M | 262.90M | 116.69M | 100.86M | 80.76M | 70.91M | 277.44M | 718.53M | 1.01B | 1.10B | 994.02M | 892.57M | 248.33M |
Gross Profit | 620.48M | 617.23M | 447.05M | 300.07M | 193.76M | 325.94M | 236.23M | 154.92M | 109.00M | 109.52M | 78.08M | 54.37M | 361.11M | 455.97M | 321.86M | 296.10M | 279.20M | 75.51M |
Gross Profit Ratio | 40.19% | 44.45% | 39.58% | 44.04% | 39.43% | 40.03% | 47.33% | 57.04% | 51.94% | 57.56% | 52.41% | 16.38% | 33.45% | 31.17% | 22.56% | 22.95% | 23.83% | 23.32% |
Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 37.59M | 19.90M | 19.52M | 21.51M | 16.54M | 15.92M | 10.68M | 11.37M | 5.99M | 1.11M | 1.36M | 517.00K | 0.00 | 44.77M | 44.10M | 81.06M | 68.40M | 26.26M |
Selling & Marketing | 11.14M | 6.60M | 7.31M | 6.83M | 11.89M | 10.86M | 4.24M | 8.34M | 9.15M | 5.54M | 3.96M | 1.87M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 412.43M | 26.50M | 26.83M | 28.34M | 28.42M | 26.79M | 14.92M | 19.71M | 15.13M | 6.65M | 5.32M | 2.38M | 0.00 | 44.77M | 44.10M | 81.06M | 68.40M | 26.26M |
Other Expenses | 0.00 | 593.00K | 2.62M | 1.80M | 1.67M | 801.00K | 4.71M | 5.50M | -18.53M | 0.00 | 0.00 | 0.00 | 0.00 | 328.00K | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 412.43M | 473.73M | 349.42M | 262.56M | 208.63M | 225.67M | 170.91M | 254.96M | 237.52M | 135.92M | 128.49M | 99.52M | 283.58M | 291.14M | 141.03M | 169.03M | 151.96M | 62.14M |
Cost & Expenses | 1.33B | 1.25B | 1.03B | 643.78M | 506.32M | 714.01M | 433.80M | 371.65M | 338.38M | 216.67M | 199.39M | 376.96M | 1.00B | 1.30B | 1.25B | 1.16B | 1.04B | 310.47M |
Interest Income | 4.08M | 3.02M | 2.19M | 1.70M | 1.64M | 1.64M | 2.20M | 1.63M | 1.37M | 4.51M | 1.87M | 5.63M | 4.65M | 1.28M | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 60.36M | 49.19M | 11.98M | 7.54M | 7.16M | 3.79M | 4.16M | 1.55M | 631.00K | 507.00K | 344.00K | 122.00K | 24.69M | 35.77M | 45.35M | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 33.50M | 35.51M | 24.66M | 19.86M | 19.99M | 20.51M | 20.42M | 97.55M | 100.47M | 18.54M | 14.40M | 12.29M | 48.73M | 55.87M | 60.73M | 61.33M | 62.78M | 26.90M |
EBITDA | 286.34M | 206.50M | 134.13M | 79.85M | 45.47M | 112.86M | 85.71M | 4.40M | -28.05M | -7.86M | 25.03M | 45.89M | 1.05B | 222.80M | 243.64M | 188.40M | 190.01M | 40.28M |
EBITDA Ratio | 18.55% | 14.16% | 10.96% | 10.27% | 5.09% | 15.40% | 19.97% | -0.07% | -11.37% | -5.31% | -8.23% | 14.72% | 12.21% | 15.23% | 16.93% | 14.60% | 16.22% | 12.44% |
Operating Income | 208.05M | 145.29M | 89.85M | 36.19M | -13.23M | 62.48M | 39.93M | -114.14M | -116.29M | -9.48M | 10.63M | 32.76M | 973.63M | 130.83M | 180.83M | 127.07M | 127.24M | 13.37M |
Operating Income Ratio | 13.48% | 10.46% | 7.95% | 5.31% | -2.69% | 7.67% | 8.00% | -42.02% | -55.41% | -4.98% | 7.14% | 9.87% | 90.18% | 8.94% | 12.68% | 9.85% | 10.86% | 4.13% |
Total Other Income/Expenses | -14.51M | -25.13M | 6.31M | 15.01M | 29.32M | -14.41M | -4.19M | -1.33M | -1.00K | -2.00K | 68.78M | 93.68M | 898.61M | -33.66M | -45.35M | -49.08M | -38.40M | 1.00K |
Income Before Tax | 193.55M | 120.14M | 96.14M | 51.20M | 16.07M | 85.87M | 61.13M | -93.15M | -116.29M | -9.48M | 10.63M | 32.76M | 973.63M | 131.16M | 135.48M | 127.07M | 127.24M | 13.37M |
Income Before Tax Ratio | 12.54% | 8.65% | 8.51% | 7.51% | 3.27% | 10.54% | 12.25% | -34.30% | -55.41% | -4.98% | 7.14% | 9.87% | 90.18% | 8.97% | 9.50% | 9.85% | 10.86% | 4.13% |
Income Tax Expense | 57.79M | 37.32M | 34.01M | 13.53M | 7.65M | 47.57M | 9.60M | -4.26M | -4.38M | -6.59M | -1.14M | -71.00K | 210.52M | 26.28M | 33.16M | 15.64M | 14.03M | 3.32M |
Net Income | 146.01M | 104.48M | 73.67M | 36.71M | 8.42M | 38.30M | 51.53M | -88.90M | -111.91M | -2.89M | 11.77M | 32.83M | 763.11M | 104.88M | 102.32M | 111.44M | 113.21M | 10.05M |
Net Income Ratio | 9.46% | 7.52% | 6.52% | 5.39% | 1.71% | 4.70% | 10.32% | -32.73% | -53.33% | -1.52% | 7.90% | 9.89% | 70.68% | 7.17% | 7.17% | 8.64% | 9.66% | 3.10% |
EPS | 9.17 | 6.71 | 4.73 | 2.37 | 0.55 | 2.61 | 3.66 | -6.72 | -8.46 | -0.22 | 0.89 | 2.48 | 6.74 | 7.92 | 7.74 | 8.44 | 8.52 | 1.62 |
EPS Diluted | 9.17 | 6.71 | 4.73 | 2.37 | 0.55 | 2.61 | 3.66 | -6.72 | -8.46 | -0.22 | 0.89 | 2.44 | 6.74 | 7.74 | 7.58 | 8.44 | 8.52 | 1.62 |
Weighted Avg Shares Out | 15.92M | 15.58M | 15.57M | 15.48M | 15.42M | 14.68M | 14.08M | 13.23M | 13.23M | 13.23M | 13.23M | 13.23M | 113.23M | 13.23M | 13.20M | 13.20M | 13.20M | 7.06M |
Weighted Avg Shares Out (Dil) | 15.92M | 15.58M | 15.57M | 15.48M | 15.42M | 14.68M | 14.08M | 13.23M | 13.23M | 13.23M | 13.23M | 13.44M | 113.23M | 13.53M | 13.20M | 13.20M | 13.20M | 7.06M |
Source: https://incomestatements.info
Category: Stock Reports